• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

JDRF launches Type 1 Diabetes Index simulation tool

September 21, 2022 By Sean Whooley

JDRF - updated logoJDRF announced today that it launched the Type 1 Diabetes Index (T1D Index) data simulation tool for measuring the impact of T1D around the globe.

The tool measures the human and public health impact type 1 diabetes has in every country. JDRF said it addresses wide gaps in data about the incidence and impact of the condition.

By leveraging data and insights from the index, attainable, country-by-country interventions may be attained. These interventions, including timely diagnosis, accessible care and funding research, could lead to cures. No cure currently exists for type 1 diabetes, JDRF said.

The Lancet Diabetes & Endocrinology published the JDRF index and accompanying research.

“As a member of the T1D community, I know many are not as fortunate as I am to have the resources necessary to live a healthy and fulfilled life,” Aaron Kowalski, JDRF CEO, said. “This is why I am so proud that significant progress has been made to understand T1D’s global impact through the T1D Index. We are calling on government and public health decision makers throughout the world to utilize the tool to identify and implement interventions that can change the trajectory of T1D.”

Experts help to build index

JDRF collaborated with partners and global experts to develop its T1D Index. It used results from a global survey of more than 500 endocrinologists and 400 publications to simulate the state of T1D.

The index highlights “missing people” who represent the number of people who would still be alive today if they had not died early due to complications from T1D. It also identifies “healthy years lost,” effectively determining time lost to ill health, disability or early death related to T1D.

According to JDRF, simulations suggest that more than 3.86 million “missing people” exist as of 2022. People “lose” an average of 32 “healthy years” to T1D if diagnosed at age 10.

Potential improvements for the T1D community

The organization said that the index leads to timely diagnosis by enabling better education and training for medical professionals. Additionally, JDRF said it creates barrier-free access to insulin and blood glucose testing strips.

It also ensures that everyone with T1D has access to technology that automates glucose monitoring (like CGM devices) and insulin delivery, such as pumps. JDRF said its index makes the case for further investment and research in emerging prevention, treatments and cures.

JDRF said that, once users identify interventions, they can take action by sharing data and findings with networks and local decision makers.

The T1D Index is supported by founding corporate sponsor, Abbott, with additional support from Lilly, Vertex Pharmaceuticals and The Leona M. and Harry B. Helmsley Charitable Trust. JDRF plans for the index to expand to include T1D’s impact on economic costs, mental health and quality of life. The data will also be broken down at regional and demographic levels.

Filed Under: Big Data, Business/Financial News, Diabetes, Featured, Technology Tagged With: Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS